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Abstract Background: The orthopedic literature has not
shown a universal and replicated difference, outside of flex-
ion, in clinical results between posterior cruciate ligament
retention and posterior cruciate ligament substitution in total
knee arthroplasty. Questions/Purposes: This study was per-
formed to compare the restoration of flexion and knee func-
tion in a large series of cruciate-retaining and cruciate-
substituting total knee arthroplasties (TKRs). In addition,
we aimed to study how other variables, such as those unique
to each surgeon, may have affected the results. Patients and
Methods: The current study evaluated 8,607 total knee
arthroplasties in 5,594 patients performed by six surgeons,
each using one of four prosthesis designs (two posterior
cruciate ligament retaining, two posterior cruciate ligament
substituting). Knees were compared at the level of cruciate-
retaining and cruciate-substituting knees, at the level of the
four prostheses, and at the level of surgeon-implant combi-
nations. Least squared means scores were obtained through
multiple linear regression, analysis of variance, and the
maximum likelihood method. Results: At the level of pos-
terior cruciate ligament treatment, posterior cruciate liga-
ment substitution as a whole showed 3.2° greater flexion
than posterior cruciate ligament retention. At the prosthesis
level, cruciate-substituting models provided greater flexion
and cruciate-retaining models provided higher function
scores. In the surgeon-implant combinations, surgeons pro-
vided mixed results that often did not reflect findings from
other levels; one surgeon's use of a posterior cruciate liga-
ment retaining prosthesis achieved 14.7° greater flexion than
the surgeon's use of a corresponding posterior cruciate liga-
ment substituting design. Conclusions: Posterior cruciate
ligament treatment is confounded by other variables, includ-
ing the operating surgeon. The arthroplasty surgeon should
choose a prosthesis based, not only on outside results, but
also on personal experience and comfort.
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Introduction
One of the most persistent issues discussed in total knee
arthroplasty is the role of retention of the posterior cruciate
ligament. There are two current options for contemporary
TKR, retention (CR) and substitution (PS), which are based
on divergent philosophies for each replacement method
which cite the importance of preservation of joint structures
and potential kinematic benefits in PCL retention, and rela-
tive ease of surgery and increased range of motion in PCL
substitution [4, 19]. Both methods have produced excellent
long-term survivorship, function, and flexion results [2, 5, 7,
8, 12–14, 21], and the published literature has not found a
significant, replicable and universal difference in their clin-
ical outcomes other than increased flexion for PCL substi-
tution [10].
For this study, the authors formed two hypotheses: (1) A
prosthesis-level comparison of individual PCL-substituting
and PCL-retaining implants would produce clinically signif-
icant differences in Knee Society evaluation measurements,
with PCL-substituting implants producing consistently
greater flexion and PCL-retaining implants producing great-
er function scores; (2) Observed clinical differences between
PCL-substituting and PCL-retaining implants may not be
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due solely to the difference in treatment of the PCL, and
more complex variables such as surgeon and patient selec-
tion should be examined.
At The Center for Hip and Knee Surgery, St. Francis
Hospital, Mooresville, Mooresville, IN, total knee replace-
ment using four predominant designs (2 are CR and 2 are
PS) has been performed for 20 years. The authors aimed to
use this large experience in an effort to provide an answer as
to the difference in flexion and Knee Society Scores that can
be expected between CR and PS designs. The authors also
aimed to assess using statistical analysis what factors such as
the operating surgeon and patient selection might contribute
to differences in outcome.
Patients and Methods
From January 1, 1983, through April 1, 2011, 15,953 total
knee arthroplasties were performed at the authors’ center;
14,153 of these TKAs were primary operations by one of six
surgeons and using one of four prosthesis most frequently
used at the center (Biomet, Warsaw, IN.; Zimmer, Warsaw,
IN.). Because this was a clinical outcomes study, exclusion
criteria that eliminated patients with less than 2 years of
follow-up was applied, after which 8,830 total knee
arthroplasties in 5,594 patients remained. Sixty-one percent
of the patients were female, their mean age at time of surgery
was 68.3 years (standard deviation, 8.9), their mean body
mass index was 31.2 kg/m2 (SD, 5.9), and the diagnosis was
osteoarthritis in 8,335 knees (96.8%), rheumatoid arthritis in
196 knees (2.3%), osteonecrosis in 61 knees (0.7%), and any
other reason in 15 knees (0.2%).
In this series of 8,830 TKAs there were 6,515 AGC
PCL-retaining knees (Biomet, Warsaw, IN) (73.8%), 376
Legacy PCL-substituting knees (Zimmer, Warsaw, IN)
(4.3%), 853 Vanguard PCL-retaining knees (Biomet)
(9.7%), and 1,086 Vanguard PCL-substituting knees
(Biomet) (12.3%) performed by six surgeons at our center
with more than 100 TKAs per year. None of these implants
have undergone any significant changes in design through-
out the study period; other prosthesis models have been used
at the authors’ center during this period, and improve-
ments in polyethylene formation have been introduced,
but the prostheses used in this study have remained un-
changed in their relevant characteristics (articulation con-
formity, patellar tracking, position of the cam-post
mechanism, etc.).
Patient follow-up was performed in person at the au-
thors’ clinic at 2 months, 6 months, and 1, 3, 5, 7, 10, 12,
15, 17, and 20 years after surgery (when available). Follow-
up appointments included Knee Society score evaluations
[9], flexion measurements using a standard goniometer, and
a standardized radiograph; measurements were performed
by either one of the six surgeons or an experienced physi-
cian’s assistant. After the appointment, data were entered
using a standardized form into a patient database maintained
at the authors’ center.
Demographic data for the patient groups for cruciate-
retaining and posterior-stabilized implants are included in
Table 1. The AGC prosthesis has a flat tibial surface in the
anteroposterior and coronal planes, while the Legacy pros-
thesis and the Vanguard prostheses have a highly
conforming tibial surface throughout. There were no differ-
ences in tibiofemoral articulation between the Vanguard
PCL-retaining and PCL-substituting designs outside of the
cam-and-post mechanism in the PCL-substituting implant.
The authors performed a retrospective analysis of the
clinical measurements found at follow-up (performed at
2 months, 6 months, and 1, 3, 5, 7, 10, 12, 15, 17, and
20 years, when available) as measured by the Knee Society
clinical rating system [9]. ANOVA/multiple linear regres-
sion with the maximum likelihood method was used to find
the least squares means (LSM) of each variable (Knee So-
ciety score, function score, flexion, pain score, stairs score,
medial lateral stability and anterior posterior stability). Each
model included for covariates preoperative alignment<−8°,
preoperative valgus >11°, bmi>41, height, age≥71, gender,
follow-up interval, and cruciate-retaining prosthesis com-
pared to posterior-stabilized prosthesis or surgeon with
nested prosthesis, or individual prosthesis. The nested model
had 24 groups (6 surgeons, 4 implant models: Surgeon 1×
AGC, Surgeon 1×Vanguard PS, Surgeon 2 x AGC, etc.).
Four of the surgeons implanted a greater variety of TKA
designs than the other two, and they were the focus of most
of the present analysis. In all models, the level of signifi-
cance for post hoc LSM-tested p values was set at p=0.05.
Source of Funding
No outside source of funding was used in support of this
study.
Results
Significant differences were found in flexion, function, and
the stairs subscore in most comparisons with every signifi-
cant difference in flexion favoring a PCL-substituting de-
sign, while significant differences in function and stairs
more often favored retention over substitution (Table 2).
No significant differences were found in the Knee Society
knee score and the pain and walk subscores between any
implant types (p>0.0528).
Table 1 Demographics of patients between posterior-stabilized and
cruciate-retaining prosthesis
Statistical measurement Posterior stabilized Cruciate retaining
n 1,093 7,514
Avg. age (SD) 66.8 (9.0) 68.4 (8.8)
% female 61.1 60.6
% diagnosis OA 98.9 96.5
Avg. BMI (SD) 33.0 (6.1) 31.0 (5.8)
Avg. pre-op flexion (SD) 102.5 (12.8) 111.6 (12.8)
% Pre-op varus<−8° 1.2% 7.4%
% pre valgus >11° 16.7% 7.7%
SD standard deviation
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The authors were unable to find differences in the knee
score (p=0.1565), function score (p=0.3112), pain subscore
(p=0.6952), stairs subscore (p=0.1442), and walk subscore
(p=0.4583) between PCL retention and PCL substitution
with the four implants included in this study. A significant
difference was found in flexion, with PCL substitution pro-
viding 3.2° greater flexion than PCL retention (117.5 vs.
114.3, p<0.0001) (Table 3).
Four-by-six matrices of all possible combinations of
surgeon, implant, and clinical measure are shown in Tables 4,
5 and 6; further analysis is limited to surgeons 1 through 4,
who implanted a greater variety of prostheses. Using a
combination of LSM score differences and intra-surgeon
ranking, the data indicate that surgeons displayed varying
levels of success with each of the four implants examined in
the study, after controlling for demographic and preoperative
factors. Overall, surgeon 1 showed relatively less success
with AGC, surgeon 2 showed relatively less success with
Vanguard CR, surgeon 3 showed relatively less success with
Vanguard PS, and surgeon 4 showed relatively less success
with Vanguard PS. For example, in knee score, surgeon 1
obtained a score 2.3 points lower with his worst prosthesis
(AGC) than with his best prosthesis (Vanguard PS); surgeon
2 obtained a score 8.3 points lower with his worst prosthesis
(Vanguard CR) than with his best prosthesis (AGC); surgeon
3 obtained a score 14.8 points lower with his worst prosthe-
sis (Vanguard PS) than with his best prosthesis (Legacy);
and surgeon 4 obtained a score 5.9 points lower with his
worst prosthesis (Vanguard PS) than with his best prosthesis
(Legacy).
In terms of clinical goals, for Pain relief, significant differ-
ences were found between the best and worst Knee Society
pain subscore in surgeon 4 (Legacy 47.4 vs. Vanguard CR
42.7, p=0.0009). Best/worst differences in surgeons 1 (p=
0.4334), 2 (p=0.2168), and 3 (p=0.1317) were not significant.
For Flexion, significant differences were found between the
greatest and least flexion in surgeons 1 (Legacy 120.9 vs.
AGC 114.7, p=0.0495), 2 (Legacy 110.4 vs. Vanguard CR
105.0, p<0.0001), 3 (Vanguard CR 121.1 vs. Vanguard PS
106.4, p<0.0001), and 4 (Vanguard PS 120.3 vs. AGC 116.3,
p<0.0001). These differences favored PCL substitution in
surgeons 1, 2, and 4 and favored PCL retention in surgeon 3.
For Function, significant differences were found between the
best and worst Knee Society function score in surgeons 1
(Vanguard CR 89.9 vs. AGC 84.0, p<0.0001) and 4 (AGC
81.9 vs. Vanguard PS 77.0, p<0.0001). The best/worst differ-
ence in surgeon 3 (Legacy 83.0 vs. AGC 74.7, p=0.0674) was
marginally significant (p<0.10), and the best/worst difference
in surgeon 2 (p=0.3960) was not significant.
Table 2 Comparison of clinical outcomes between TKA designs
Implant Number LSM Effect size (SD)a p value
Knee score
Legacy 376 88.2 2.2 (1.1) 0.0528
Vanguard CR 853 86.1 0.0 (1.1) 0.9839
Vanguard PS 1,086 87.2 1.2 (1.0) 0.2299
AGC 6,515 86.1 Base Base
Pain subscore
Legacy 376 47.8 0.3 (0.4) 0.4821
Vanguard CR 853 47.4 −0.1 (0.4) 0.7595
Vanguard PS 1,086 47.5 −0.0 (0.3) 0.9318
AGC 6,515 47.5 Base Base
Flexion
Legacy 376 117.3 3.2 (0.5) <0.0001
Vanguard CR 853 113.7 −0.4 (0.6) 0.4857
Vanguard PS 1,086 117.5 3.4 (0.5) <0.0001
AGC 6,515 114.1 Base Base
Function score
Legacy 376 85.1 1.4 (0.8) 0.0853
Vanguard CR 853 85.9 2.3 (0.9) 0.0095
Vanguard PS 1,086 83.2 −0.4 (0.7) 0.5577
AGC 6,515 83.6 Base Base
Stairs subscore
Legacy 376 41.2 1.0 (0.5) 0.0273
Vanguard CR 853 42.7 2.5 (0.5) <0.0001
Vanguard PS 1,086 40.0 −0.2 (0.4) 0.5588
AGC 6,515 40.2 Base Base
Walk subscore
Legacy 376 45.0 0.4 (0.5) 0.5057
Vanguard CR 853 44.6 −0.0 (0.6) 0.9468
Vanguard PS 1,086 44.1 −0.6 (0.5) 0.2002
AGC 6,515 44.7 Base Base
AP stability
Legacy 376 10.01 0.04 (0.02) 0.0087
Vanguard CR 853 10.05 0.08 (0.01) <0.0001
Vanguard PS 1,086 10.01 0.05 (0.01) 0.0010
AGC 6,515 9.97 Base Base
ML stability
Legacy 376 14.98 −0.01 (0.02) 0.6040
Vanguard CR 853 15.00 0.01 (0.02) 0.4168
Vanguard PS 1,086 15.00 0.01 (0.01) 0.5664
AGC 6,515 14.99 Base Base
aEffect size compared to AGC with standard deviation in parenthesis
Table 3 Overall comparison of clinical results after TKA using either
PCL-retaining (CR) or PCL-substituting (PS) prostheses
Treatment Number LSM Effect size (SD)a p value
Knee score
CR 7,368 86.3 −1.1 (0.7) 0.1565
PS 1,462 87.3 Base Base
Pain subscore
CR 7,368 47.5 −0.1 (0.3) 0.6952
PS 1,462 47.6 Base Base
Flexion
CR 7,368 114.3 −3.2 (0.4) <0.0001
PS 1,462 117.5 Base Base
Function score
CR 7,368 84.1 0.6 (0.6) 0.3112
PS 1,462 83.5 Base Base
Stairs subscore
CR 7,368 40.6 0.5 (0.3) 0.1442
PS 1,462 40.1 Base Base
Walk subscore
CR 7,368 44.7 0.3 (0.4) 0.4583
PS 1,462 44.4 Base Base
AP stability
CR 7,368 9.98 −0.02 (0.01) 0.1520
PS 1,462 10.00 Base Base
ML stability
CR 7,368 14.99 0.00 (0.01) 0.6525
PS 1,462 14.99 Base Base
aEffect size compared with PCL substitution, with standard deviation
in parenthesis
HSSJ (2014) 10:107–115 109
Table 4 Knee Society knee scores and subscores for surgeon-implant combinations
Surgeon
Implant Statistical measurement 1 2 3 4 5 6
Knee score
Legacy n 2 306 3 63 2b 0
Least squared mean 91.2 84.6 91.0 87.5
LSM rank w/in surgeon 2 3 1 1
Effect size (SD)a 5.3 (3.3) −1.4 (1.1) 5.1 (2.8) 1.6 (2.6)
p value 0.1066 0.2174 0.0672 0.5445
VCR n 369 216 37 146b 85b 0
Least squared mean 90.8 79.7 86.94
Rank w/in surgeon 3 4 2
Effect size (SD) 4.9 (1.4) −6.2 (2.1) 1.0 (3.0)
p value 0.0005 0.0039 0.7325
VPS n 319 328 28 294 117 0
Least squared mean 91.9 84.8 76.2 81.6 90.3
Rank w/in surgeon 1 2 4 3
Effect size (SD) 6.0 (1.3) −1.1 (2.3) −9.7 (2.9) −4.3 (2.2) 4.4 (3.1)
p value <0.0001 0.6316 0.0008 0.0573 0.1646
AGC n 354 851 2,887 459 0 1,964
Least squared mean 89.6 88.0 83.8 85.9 85
Rank w/in surgeon 4 1 3 2
Effect size (SD) 3.6 (1.0) 2.1 (2.4) −2.1 (0.9) Base −0.9 (1.0)
p value 0.0004 0.3893 0.0225 Base 0.3607
Best vs. worst LSM difference 2.3 8.3 14.8 5.9
p value 0.0336 0.0056 0.0001 0.0680
Pain subscore
Legacy n 2 306 3 63 2 0
Least squared mean 50.0 47.1 49.2 47.4 50.6
LSM rank w/in surgeon 1 3 3 1 1
Effect size (SD)a 4.0 (2.4) 1.1 (0.4) 3.2 (2.0) 1.3 (0.7) 4.6 (3.2)
p value 0.0907 0.0056 0.1099 0.0524 0.1465
VCR n 369 216 37 146 85b 0
Least squared mean 48.9 46.88 50.49 42.69
Rank w/in surgeon 3 4 1 4
Effect size (SD) 2.9 (0.6) 0.8 (0.6) 4.5 (2.1) −3.3 (1.3)
p value <0.0001 0.1555 0.0375 0.0093
VPS n 319 328 28 294 117 0
Least squared mean 49.6 47.6 45.87 44.39 48.39
Rank w/in surgeon 2 2 2 3 2
Effect size (SD) 3.6 (0.6) 1.6 (0.5) −0.2 (1.7) −1.6 (0.5) 2.4 (1.4)
p value <0.0001 0.0007 0.9252 0.0010 0.0958
AGC n 354 851 2,887 459 0 1,964
Least squared mean 48.2 48.2 47.3 46.0 47.6
Rank w/in surgeon 4 1 4 2
Effect size (SD) 2.2 (0.4) 2.1 (1.0) 1.3 (0.3) Base 1.6 (0.4)
p value <0.0001 0.0247 <0.0001 Base <0.0001
Best vs. worst LSM difference 1.8 1.3 3.2 4.7 2.2
p value 0.4334 0.2168 0.1317 0.0009 0.5170
Flexion
Legacy n 2 306 3 63 2 0
Least squared mean 120.9 110.4 111.0 117.6 126.73
LSM rank w/in surgeon 1 1 3 2 1
Effect size (SD)a 4.6 (3.2) −5.9 (0.5) −5.2 (2.6) 1.3 (0.9) 10.5 (5.5)
p value 0.1443 <0.0001 0.0474 0.1654 0.0554
VCR n 369 216 37 146 85b 0
Least squared mean 115.8 105.0 121.1 116.6
Rank w/in surgeon 3 4 1 3
Effect size (SD) −0.5 (0.8) −11.3 (0.8) 4.8 (2.9) 0.3 (1.7)
p value 0.5354 <0.0001 0.0942 0.8397
VPS n 319 328 28 294 117 0
Least squared mean 120.1 109.6 106.4 120.3 123.0
Rank w/in surgeon 2 2 4 1 2
Effect size (SD) 3.8 (0.9) −6.6 (0.6) −9.9 (2.3) 4.1 (0.7) 6.8
p value <0.0001 <0.0001 <0.0001 <0.0001 0.0010
AGC n 354 851 2,887 459 0 1,964
Least squared mean 114.7 107.2 117.2 116.3 109.2
Rank w/in surgeon 4 3 2 4
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In the Vanguard family of prostheses (Vanguard CR vs.
Vanguard PS), in which the only difference between the two
prosthesis designs are in the treatment of the PCL, the
authors were unable to show a statistically significant dif-
ference between most comparisons (Table 7). Those that did
show significant differences were the knee score for surgeon
3 (CR 86.9 vs. PS 76.2, p=0.0069), flexion for all four
surgeons (surgeons 1, 2, and 4 favoring PS, surgeon 3
favoring CR; surgeon 4 p=0.0348, all others p<0.0001),
and the stairs subscore for surgeon 1 (CR 44.33 vs. PS
41.86, p=0.0024). The differences in knee score for surgeon
2 (p=0.0770), the pain subscore for surgeon 3 (p=0.0873),
and the function score for surgeon 1 (p=0.0925) were mar-
ginally significant.
Discussion
PCL-retaining and PCL-substituting total knee arthroplasties
have provided excellent results in long-term follow-up, both
in survivorship and in clinical measurements like range of
motion and function [2, 5, 7, 8, 12–14, 21]. Because the
debate between PCL retention and PCL substitution has
lasted since at least the 1970s [11, 18, 20], and because the
literature has not provided a consistent conclusion on the
matter [10], it is difficult to determine which design provides
consistently better outcomes. PCL substitution is often pre-
ferred in the absence of definitive differences between the
two options due to the experience and attention required in
PCL-retaining designs to correctly balance the PCL [4, 19].
One recent study [1, 6], however, reported significantly
greater survivorship for PCL-retaining knees at 15 years.
The current investigation found results within one pros-
thesis generation (Vanguard) that are largely, but not
completely, consistent with those published previously.
Three of the four surgeons obtained greater flexion with
the Vanguard PS implant than with the CR version, in
agreement with the results of a Cochrane analysis [11];
surgeon 1 also obtained higher stairs subscores with Van-
guard CR than with Vanguard PS. Other comparisons, how-
ever, did not conform to what has been expected of PCL-
retaining and PCL-substituting systems. The Vanguard stairs
scores for surgeons 2, 3 and 4 were not found to be signif-
icantly different, and surgeon 3, in even greater contrast,
achieved more flexion with Vanguard CR than with Van-
guard PS (121.1° vs. 106.4°).
These results suggest that a deeper examination of the
influence of operating surgeon is required before a signifi-
cant and independent difference in PCL results can be de-
clared. The current study began with one hypothesis
(hypothesis 1 as described in the Introduction) as an exam-
ination of each implant model’s independent influence on
clinical outcome; the original goal was to conclude whether
PCL substitution or PCL retention provided more favorable
universal results. Because of the inconsistent conclusions
from other investigators studying PCL treatment in TKA,
however, the authors felt that a second hypothesis was
required, thus the projection that examinations at other
levels would elucidate further influences on TKA success.
A nested model of prosthesis within surgeonwas necessary
as the surgeon variable seemed to confound the authors’ pre-
liminary results across both PCL treatment and implant gener-
ation, preventing a conclusion on the efficacy of the two PCL
treatments independent of the operating surgeon. This nested
model through successive layers has shown results that, in the
uppermost layer of PCL retention versus PCL substitution,
only showed a difference in flexion; many differences did
not surface until the surgeon variable was considered.
This study follows a line of evidence gathered in previous
published studies from the authors’ center. A study published
in 2004 [3] cited abnormal anatomic knee alignment along
with preoperative factors like morbid obesity and ligamentous
imbalance as the main mechanisms of failure in AGC cruciate-
retaining total knee replacement. Further studies expounded
on the influence of postoperative [17] and preoperative [15]
anatomic alignment on failure rates, while another [16] con-
cluded that, even if the PCL is completely excised during
TKA, the surgeon need not convert to a posterior-stabilized
prosthesis if anteroposterior and coronal stability are main-
tained. These studies collectively argue that prosthesis selec-
tion with regard to the PCL may not affect the results of TKA
as much as do other variables like anatomic alignment or
patient comorbidities. More studies are needed to substantiate
this argument, but the present series of published manuscripts
may currently provide enough rationale to merit its application
in a clinical setting.
A recent study by Abdel et al. [1] of 8,117 primary TKAs
(Press-Fit Condylar, DePuy, Warsaw, IN; and Genesis I,
Smith & Nephew, Memphis, TN) performed between 1988
and 1998 reported significantly greater survivorship rates for
cruciate-retaining implants, with 15-year survivorship for
PCL retention at 89.8% versus 76.5% for PCL substitution
Effect size (SD) −1.6 (0.6) −9.1 (1.3) 0.9 (0.4) Base −7.1 (0.5)
p value 0.0050 <0.0001 0.0342 Base <0.0001
Best vs. worst LSM difference 6.2 5.4 14.7 4.0 3.7
p value 0.0495 <0.0001 <0.0001 <0.0001 0.5257
aEffect size compared to surgeon 4×AGC, with standard deviation in parenthesis
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Table 5 Knee Society function scores and subscores for surgeon-implant combinations
Surgeon
Implant Statistical measurement 1 2 3 4 5 6
Function score
Legacy n 2 306 3 63 2 0
Least squared mean 89.3 88.5 83.0 81.6 91.8
LSM rank w/in surgeon 2 1 1 2 1
Effect size (SD)a 7.3 (5.2) 6.5 (0.8) 1.0 (4.3) −0.4 (1.5) 9.9 (6.9)
p value 0.1547 <0.0001 0.8108 0.8055 0.1513
VCR n 369 216 37 146 85b 0
Least squared mean 89.9 87.4 78.8 78.7
Rank w/in surgeon 1 4 2 3
Effect size (SD) 8.0 (1.2) 5.5 (1.3) −3.1 (4.7) −3.3 (2.8)
p value <0.0001 <0.0001 0.5086 0.2422
VPS n 319 328 28 294 117 0
Least squared mean 87.5 87.8 74.7 77.0 83.9
Rank w/in surgeon 3 3 3 4 2
Effect size (SD) 5.5 (1.2) 5.9 (1.0) −7.3 (3.7) −4.9 (1.1) 2.0 (3.1)
p value <0.0001 <0.0001 0.0489 <0.0001 0.5150
AGC n 354 851 2,887 459 0 1,964
Least squared mean 84.0 88.3 75.2 81.9 88.0
Rank w/in surgeon 4 2 4 1
Effect size (SD) 2.0 (0.9) 6.4 (2.1) −6.8 (0.7) Base 6.1 (0.8)
p value 0.0251 0.0021 <0.0001 Base <0.0001
Best vs. worst LSM difference 5.9 1.1 7.8 4.9 7.9
p value <0.0001 0.3960 0.0674 <0.0001 0.2931
Stairs subscore
Legacy n 2 306 3 63 2 0
Least squared mean 39.2 43.6 34.6 40.2 46.8
LSM rank w/in surgeon 3 3 2 1 1
Effect size (SD)a −0.5 (2.8) 3.9 (0.5) −5.2 (2.4) 0.5 (0.8) 7.0 (3.8)
p value 0.8610 <0.0001 0.0290 0.5616 0.0630
VCR n 369 216 37 146 85b 0
Least squared mean 44.3 43.6 35.2 37.2
Rank w/in surgeon 1 1 1 3
Effect size (SD) 4.6 (0.7) 3.9 (0.7) −4.5 (2.6) −2.5 (1.5)
p value <0.0001 <0.0001 0.0806 0.0992
VPS n 319 328 28 294 117 0
Least squared mean 41.9 43.3 34.5 36.5 41.9
Rank w/in surgeon 2 4 3 4 2
Effect size (SD) 2.1 (0.7) 3.6 (0.5) −5.3 (2.0) −3.2 (0.6) 2.2 (1.7)
p value 0.0017 <0.0001 0.0095 <0.0001 0.1969
AGC n 354 851 2,887 459 0 1,964
Least squared mean 39.0 43.6 33.2 39.7 44.0
Rank w/in surgeon 4 2 4 2
Effect size (SD) −0.8 (0.5) 3.8 (1.1) −6.6 (0.4) Base 4.3 (0.5)
p value 0.1170 0.0007 <0.0001 Base <0.0001
Best vs. worst LSM difference 5.3 0.3 2.0 3.7 4.9
p value <0.0001 0.7404 0.4129 <0.0001 0.2386
Walk subscore
Legacy n 2 306 3 63 2 0
Least squared mean 49.4 45.7 48.9 42.5 47.6
LSM rank w/in surgeon 1 2 1 2 1
Effect size (SD)a 6.4 (3.3) 2.7 (0.5) 5.9 (2.7) −0.5 (1.0) 4.6 (4.4)
p value 0.0510 <0.0001 0.0326 0.6199 0.2942
VCR n 369 216 37 146 85b 0
Least squared mean 46.4 44.7 44.1 42.5
Rank w/in surgeon 2 4 2 3
Effect size (SD) 3.4 (0.8) 1.7 (0.8) 1.1 (3.0) −0.5 (1.8)
p value <0.0001 0.0416 0.7189 0.7905
VPS n 319 328 28 294 117 0
Least squared mean 45.9 45.2 39.8 41.3 45.3
Rank w/in surgeon 3 3 4 4 2
Effect size (SD) 2.9 (0.8) 2.2 (0.6) −3.2 (2.4) −1.7 (0.7) 2.3 (2.0)
p value 0.0003 0.0006 0.1699 0.0141 0.2506
AGC n 354 851 2,887 459 0 1,964
Least squared mean 45.5 46.0 42.9 43.0 45.0
Rank w/in surgeon 4 1 3 1
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Table 6 Stability measurements for surgeon-implant combinations
Surgeon
Implant Statistical measurement 1 2 3 4 5 6
Anteroposterior stability
Legacy n 2 306 3 63 2 0
Least squared mean 10.01 10.00 10.00 10.00 9.99
LSM rank w/in surgeon 2 4 2 3 2
Effect size (SD)a 0.01 (0.10) 0.00 (0.02) 0.00 (0.08) 0.00 (0.03) −0.00 (0.13)
p value 0.9079 0.7611 0.9652 0.9843 0.9713
VCR n 369 216 37 146 85b 0
Least squared mean 10.01 10.01 9.99 10.01
Rank w/in surgeon 1 2 3 1
Effect size (SD) 0.01 (0.02) 0.01 (0.02) −0.01 (0.09) 0.01 (0.05)
p value 0.5981 0.7340 0.9523 0.8844
VPS n 319 328 28 294 117 0
Least squared mean 9.98 10.00 9.98 10.00 10.00
Rank w/in surgeon 3 3 4 2 1
Effect size (SD) −0.02 (0.02)
p value 0.5227
AGC n 354 851 2,887 459 0 1,964
Least squared mean 9.87 10.01 10.00 10.00 9.99
Rank w/in surgeon 4 1 1 4
Effect size (SD) −0.13 0.01 (0.04) 0.01 (0.01) Base −0.01 (0.01)
p value <0.0001 0.8232 0.6984 Base 0.5274
Best vs. worst LSM difference 0.14 0.01 0.02 0.01 0.01
p value <0.0001 0.9190 0.7552 0.8844 0.9242
Mediolateral stability
Legacy n 2 306 3 63 2 0
Least squared mean 14.99 14.98 15.00 15.00 15.00
LSM rank w/in surgeon 1 4 3 2 2
Effect size (SD)a −0.01 (0.10) −0.02 (0.01) −0.01 (0.08) 0.00 (0.03) −0.00 (0.12)
p value 0.9254 0.2022 0.9394 0.9206 0.9846
VCR n 369 216 37 146 85b 0
Least squared mean 14.98 15.01 15.00 15.00
Rank w/in surgeon 2 1 1 4
Effect size (SD) −0.02 (0.02) 0.00 (0.02) −0.00 (0.08) −0.00 (0.05)
p value 0.4388 0.8665 0.9569 0.9807
VPS n 319 328 28 294 117 0
Least squared mean 14.98 15.00 15.00 15.00 15.00
Rank w/in surgeon 3 2 2 1 1
Effect size (SD) −0.02 (0.02) 0.00 (0.02) −0.00 (0.07) 0.00 (0.02) 0.00 (0.05)
p value 0.3319 0.9035 0.9389 0.8792 0.9895
AGC n 354 851 2,887 459 0 1,964
Least squared mean 14.97 15.00 14.99 15.00 14.99
Rank w/in surgeon 4 3 4 3
Effect size (SD) −0.03 (0.02) −0.00 (0.04) −0.01 (0.01) Base −0.01 (0.01)
p value 0.0471 0.9485 0.5572 Base 0.3472
Best vs. worst LSM difference 0.02 0.03 0.01 0.00 0.00
p value 0.7943 0.3048 0.9751 0.9352 0.9815
aEffect size compared to surgeon 4 x AGC, with standard deviation in parenthesis
bThese observations were not full rank in the model because of missing values such as preoperative alignments or intermediate follow-up
Effect size (SD) 2.5 (0.6) 3.0 (1.3) −0.1 (0.4) Base 2.1 (0.5)
p value <0.0001 0.0233 0.7773 Base 0.0001
Best vs. worst LSM difference 3.9 1.3 9.1 1.7 2.3
p value 0.3605 0.3554 0.0109 0.0141 0.6221
aEffect size compared to surgeon 4 x AGC, with standard deviation in parenthesis




Statistical measurement 1 2 3 4 5 6
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(p<0.001). The difference extended to those knees with
preoperative flexion contracture and angular deformity
(89.8% vs. 70.5%, p=0.04); however, only 52 PCL-
substituting knees in this group were followed for 15 years.
A concurrent comment [6] noted this limitation, as well as
the possibility of differences in sterilization and polyethyl-
ene oxidation between the two groups caused by PCL sub-
stitution’s limited use in the early phase of the study period.
A cited strength of the above study is the use of data
exclusively from surgeons performing at least 50 total knee
arthroplasties per year. This technique controls for the influ-
ence of surgeons who are relatively inexperienced with
TKA; it does not, however, address any preferences or
familiarities that experienced orthopedic surgeons may hold
toward a specific implant.
This study is a retrospective review of prospectively
gathered data, so any findings must be considered in this
light; however, the sample size and statistical methods coun-
teract the weakness from which a retrospective cohort study
typically suffers. Comparisons between the various designs
in this study were only made after the use of generalized
linear regression and the maximum likelihood method to
minimize the influence of confounding variables. This sta-
tistical test was used on a large set of nearly 9,000 knees,
which produced sufficient power to determine differences
between most individual surgeon-prosthesis combinations.
A second possible limitation arises from the prevalence of
each TKA design at the center. The surgeon-authors and
their colleagues implanted more PCL-retaining than PCL-
substituting TKAs, and they may have used the PCL-
substituting design only in patients with the worst deformi-
ties, such as extreme preoperative varus or valgus. These
cases, however, did not unduly influence the results de-
scribed here because the surgeons only used PCL-substitut-
ing implants in these cases to compensate for the deformity,
not to specifically increase flexion in a preoperatively low-
flexion patient. There was no systematic bias in the surgeons
involved in this study that would result in a disproportionate
amount of any preoperative patient population receiving one
of the four implant designs.
Future studies, especially from large-volume centers
with high statistical power, should use a nested model to
examine the possible interacting variables of surgeon and
implant design. Such evaluations may show that it is more
important, not for the surgeon to choose which total knee
design provides universally improved results, but instead for
the surgeon to determine which total knee design provides
consistently favorable results for the surgical technique he or
she feels comfortable with in practice. In this case, the
surgeon may find that different prostheses may provide
different advantages in function, flexion, and pain relief,
and that these advantages (and any possible disadvantages)
may not extend to other surgeons at his/her practice or in the
orthopedic field. The same conditions in situ (preoperative
angular deformity, anteroposterior stability, etc.) may spur
different surgeons to implant different arthroplasty models
based on their familiarity and technique, while still obtaining
good or excellent long-term clinical results.
Previous studies have asserted that PCL-substituting to-
tal knee arthroplasty provides more consistent results than
Table 7 Clinical results of TKA in 12 implant-surgeon combinations within the Vanguard prosthesis family
Surgeon
1 2 3 4
CR PS CR PS CR PS CR PS
Knee score 90.8 91.9 79.7 84.8 86.9 76.2 n/a 81.6
Difference 1.0 1.0 5.1 5.1 10.7 10.7
p-value 0.4793 0.4793 0.0770 0.0770 0.0069 0.0069
Pain subscore 48.9 49.6 46.9 47.6 50.5 45.9 42.7 44.4
Difference 0.7 0.7 0.7 0.7 4.6 4.6 1.7 1.7
p-value 0.2787 0.2787 0.2440 0.2440 0.0873 0.0873 0.1969 0.1969
Flexion 115.8 120.1 105.0 109.6 121.1 106.4 116.6 120.3
Difference 4.3 4.3 4.7 4.7 14.7 14.7 3.7 3.7
p-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.0348 0.0348
Function score 89.9 87.5 87.4 87.8 78.8 74.7 78.7 77.0
Difference 2.5 2.5 0.4 0.4 4.2 4.2 1.6 1.6
p-value 0.0925 0.0925 0.7745 0.7745 0.4765 0.4765 0.5684 0.5684
Stairs subscore 44.3 41.9 43.6 43.3 35.2 34.5 37.2 36.5
Difference 2.5 2.5 0.3 0.3 0.8 0.8 0.7 0.7
p-value 0.0024 0.0024 0.7404 0.7404 0.8103 0.8103 0.6669 0.6669
Walk subscore 46.4 45.9 44.7 45.2 44.1 39.8 42.5 41.3
Difference 0.5 0.5 0.5 0.5 4.3 4.3 1.2 1.2
p-value 0.6049 0.6049 0.5456 0.5456 0.2512 0.2512 0.4997 0.4997
AP stability 10.01 9.98 10.01 10.00 9.99 9.98 10.01 10.00
Difference 0.03 0.03 0.01 0.01 0.01 0.01 0.01 0.01
p-value 0.3344 0.3344 0.8748 0.8748 0.9194 0.9194 0.9163 0.9163
ML stability 14.98 14.98 15.01 15.00 15.00 15.00 15.00 15.00
Difference 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00
p-value 0.8507 0.8507 0.9444 0.9444 0.9959 0.9959 0.9352 0.9352
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PCL-retaining TKA, particularly in flexion. In light of the
data from the present study and from documented success
with PCL retention, however, the operating surgeon may
prove to be a substantially influential variable of overall
TKA success than previously thought. If this is the case,
then it is the surgeon’s responsibility to establish which
TKA design is most suited to his or her operative technique.
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